©2024 Stanford Medicine
PET/MRI in the Diagnosis of Chronic Pain
Recruiting
I'm InterestedTrial ID: NCT03556137
Purpose
Several studies have implicated involvement of sigma-1 receptors (SR1s) in the generation of
chronic pain, while others are investigating anti SR1 drugs for treatment of chronic pain.
Using [18F]-FTC-146 and positron emission tomography/magnetic resonance imaging (PET/MRI),
the investigators hope to identify the source of pain generation in patients with chronic
pain. The purpose of this study is to compare the uptake of [18F]FTC-146 in healthy
volunteers to that of individuals suffering from chronic pain.
Official Title
Use of [18F]FTC-146 PET/MRI in the Diagnosis of Chronic Pain
Stanford Investigator(s)
Anand Veeravagu
Associate Professor of Neurosurgery and, by courtesy, of Orthopaedic Surgery
Eligibility
Inclusion Criteria:
Healthy Volunteers:
1. At least 18 years old.
2. Covid Vaccination status: Vaccinated or unvaccinated subjects who received a negative
test result from the Covid test within 72 hours of the scan.
Pain Patients:
1. At least 18 years old.
2. Chronic pain (nociceptive, neuropathic or mixed pain) lasting greater than 2 months.
3. Pain level of at least 4/10 on a 0-10 Comparative Pain Scale.
4. Covid Vaccination status: Vaccinated or unvaccinated subjects who received a negative
test result from the Covid test within 72 hours of the scan.
Exclusion Criteria:
Healthy Volunteers:
1. Pain
2. Pain Medication
3. MRI incompatible
4. Pregnant or nursing
5. Non-English speaker
6. Claustrophobic
Pain Patients:
1. MRI incompatible
2. Pregnant or nursing
3. Non-English speaker
4. Claustrophobic
Intervention(s):
drug: [18F]FTC-146
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Adrian Valladarez, BA